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Aims. Budd-Chiari Syndrome (BCS) is a rare vascular disease of the liver caused by the obstruction of the hepatic venous outflow
located from the small hepatic venules up to the entrance of the inferior vena cava (IVC) into the right atrium. Current prognostic
indexes are suboptimal for an individual prognostic assessment and subsequent management of patients with BCS. Liver (LSM)
and spleen (SSM) stiffnessmeasurements are widely validated prognostic tools in hepatology, but the evidence in patients with BCS
is limited.This paper describes LSM and SSM in patients with BCS and their correlation with clinical, biochemical, and ultrasound
findings from the same patients.Methods. We investigated a case series of seven patients with BCS diagnosis and available LSM and
SSM evaluated by transient elastography (TE). Biochemical, imaging, and endoscopic findings nearest to the TE evaluation were
recorded. Clinical outcomes and BCS evolution were described for each patient.When available, repeated TE assessmentswere also
recorded. Results. Patients with acute nonfulminant manifestation of BCS presented near-the-upper-limit values (75 kPa) of LSM
and SSM, which often persist until the placement of a transjugular intrahepatic portosystemic shunt (TIPS). On the other hand, TE
values were markedly lower in patients with compensated BCS. In some patients with repeated TE measurement years after TIPS
placement, LSM had decreased to values of <10 kPa years. SSM changes in these patients were, however, less evident. Conclusions.
Extremely elevated values of LSM and SSM are suggestive of BCS.The evaluation of both LSM and SSM by TE could help clinicians
in the initial evaluation, risk stratification, and therapy response monitoring of patients with BCS.
1. Introduction
Budd-Chiari Syndrome (BCS) is defined as the obstruction
of hepatic venous outflow located from the small hepatic
venules up to the entrance of the inferior vena cava (IVC)
into the right atrium [1]. To date, various prognostic indices
(PIs) similar to the Child-Pugh classification, such as the
Rotterdam [2] or Clichy Score [3], have been proposed to
predict transplantation- (OLT-) free or overall survival in
BCS patients [1]. However, these PIs have a relatively low
predictive ability [4, 5] and are thus not suitable for an indi-
vidual prognostic assessment andmanagement [1].Moreover,
no specific noninvasive predictors of recanalization, portal
hypertension (PH) severity, risk of decompensation event, or
transjugular-intrahepatic-portosystemic shunt (TIPS) dys-
function are available. Yet such predictors would be very
helpful for clinicians in monitoring BCS patients, in order to
guide the therapeutic approach and evaluate its response.
Noninvasive tests (NITs), such as liver (LSM) and spleen
(SSM) stiffness measurements, have been widely validated as
accurate surrogates of PH [6] and its complications, such as
high-risk esophageal varices [7, 8] or hepatic decompensation
[9, 10], in patients with advanced chronic liver disease
(ACLD). To our knowledge, only two studies [11, 12] have
described LSM and its changes after endovascular treatment
in BCS patients, suggesting that LSM reflects liver congestion
rather than the fibrosis stage in these cases. On the other
hand, SSM has not yet been described in this context. Studies
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exploring the prognostic role of such parameters in the
context of vascular liver diseases, including BCS, are therefore
needed [6].
This paper discusses a case series of patients diagnosed
with BCS and their LSM and SSM by transient elastography
(TE).
2. Case Presentations
Table 1 summarizes the main demographic, clinical, and
radiological findings in our patient cohort with BCS.
(1) A 34-year-old female with essential thrombo-
cythemia (ET) presented to the emergency unit
for body weight gain and increase in abdominal
circumference; nocturnal pruritus and abdominal
pain had been present since pregnancy. Doppler-
ultrasound (US) established a diagnosis of BCS.
An upper endoscopy (EGD) showed the presence
of grade 1 esophageal varices (EV) and mild portal
hypertensive gastropathy (PHG). TE evaluation at
diagnosis showed LSM and SSM values of 75 kPa at
both sides.
For the following two years, caudate lobe hyper-
trophy and a macronodular liver pattern (>2.5 cm)
developed. Most importantly, ascites was resistant
and intolerant to diuretic therapy, leading to the
readmission of the patient for severe hyponatremia
and massive pleural effusion. TIPS was thus placed.
In the following year, no liver-related complications
were registered. EGD showed no signs of EV or PHG.
At concomitant TE control, LSM was significantly
reduced to 8 kPa, but high values of SSM persisted
(65.2 kPa).
(2) A 65-year old female with a history of persistent
abdominal pain presented with a recent increase in
abdominal circumference. The CT scan evaluation
provided the diagnosis of BCS. No EV or PHG were
shown at EGD. LSM and SSM were both 75 kPa. The
hematological evaluation established anETdiagnosis.
In the following two years, EGD showed EV grade
1 and the patient developed recurrent episodes of
ascites. At the last decompensating event, LSM and
SSM were both 75 kPa. Accordingly, TIPS was placed
and an evaluation for liver transplant was started. In
the following month, the patient underwent OLT and
no signs of BCS recurrence have been reported since
then.
(3) A 25-year-old male with an initial diagnosis of
decompensated cryptogenic cirrhosis was referred
for OLT evaluation due to severe PH with repeated
bleeding episodes. In our unit, Doppler-US showed
obliterated hepatic veins (HVs) and signs of severe
PH. BCSdiagnosiswas confirmed at vena cavography.
LSM and SSM were both 75 kPa.
At EGD controls, EV persisted (G1with red signs) and
PHG became severe. TIPS placement was attempted,
but was unsuccessful. Consequently, in the following
year, the patient developed numerous decompen-
sating events. During one of these episodes, the
bleeding could not be controlled, thus urgent OLT
was attempted and successfully carried out.
(4) A 52-year-oldmale was admitted to our unit with sus-
pected BCS. Vena cavography andHVcatheterization
indicated ICV thrombosis. Liver biopsy highlighted
macro-vesicular steatosis, thus ruling out the pres-
ence of significant fibrosis. EGD screening revealed
the presence of grade 1 gastric varices.
In the following months, the patient presented several
bleeding episodeswhich finally led to TIPS placement
one year after BCS diagnosis. At TE evaluation before
the intervention, LSM and SSM were both 75 kPa.
During a follow-up of over ten years, TIPS remained
patent and no variceal bleeding or ascites occurred.
At TE evaluation, 10-year post-TIPS placement, LSM
was 7.3 kPa, while high values of 75 kPa for SSM were
reported.
(5) A 65-year-old female with BCS diagnosis presented
the following medical history: long-standing Poly-
cythemia Vera (PV); initial diagnosis of cryptogenic
cirrhosis and idiopathic PH from diffuse nodular
regenerative hyperplasia (NRH). Subsequently, ser-
rated stenosis of right and left HVs were demon-
strated. After percutaneous transluminal angioplasty
(PTA) and TIPS placement, the patient remained
compensated and was subsequently lost at follow-up.
During evaluation in our center: EGD showed mild
PHG, but no EV; US described signs suggestive of
advanced liver disease, minimal ascites and normal
TIPS flow velocity. However, in the following year,
TIPS was obstructed and subsequently compensated
by recanalization of the paraumbilical vein. LSM and
SSM at this time were both 75 kPa. No events of
clinical decompensation were reported in the follow-
up although EGD showed the development of grade 1
EV.
(6) A 61-year-old female was referred to our center
for mild and diffuse abdominal pain. Doppler-US
described a narrowed and partly visible right HV.
Caudate lobe hypertrophy andmacronodules (>2 cm)
were also described in the liver. No signs of portal
hypertension were present. LSM and SSM were 34.8
kPa and 38.5 kPa, respectively.
At follow-up over six years later, no decompensating
events had developed. A repeated TE evaluation
showed slightly reduced LSM and SSM values.
(7) A 23-year-old female with Behc¸et’s disease was
referred to our center for persistent fever. At CT-
scan assessment, however, stenosed right and leftHVs
were described. Liver biopsy showed unspecific signs
and ruled out significant fibrosis. At Doppler-US, no
ascites was present, but a patent paraumbilical vein
was observed, as well as a slight splenomegaly. EGD
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ruled out the presence of EV. LSM and SSM were 14.3
kPa and 47.2 kPa, respectively.
During follow-up, no ascites or other hepatic decom-
pensation events developed. At TE control three years
after diagnosis, LSM and SSM were 11.8 and 40 kPa
respectively.
3. Discussion
The results of the present study suggest that LSM and
SSM could help in stratifying for the risk of PH-related
complications as well as monitoring therapy response in BCS
patients.
LSM evaluation by TE represents the most studied and
validated ultrasonography technique to noninvasively assess
the degree of liver fibrosis [13]. This method allows assess-
ing the biomechanical properties of the liver by recording
the propagation of shear-waves caused by a mechanically
induced impulse applied at the tissue surface [14]; the velocity
is then converted to Young’s modulus value expressed in
kPa [15]. In healthy people, normal values of LSM range
between 4.4 and 5.5 kPa [16, 17], whereas values ≥7.1 kPa
indicate moderate fibrosis (F2) [13]. In ACLD patients, LSM
also correlates with the hepatic venous pressure gradient
(HVPG) [6, 8, 18], the gold standard of PH evaluation [19],
and therefore it could be used to indirectly assess PH in
such patients [6]. According to the last Baveno Consensus on
PH, LSM values of >20-25 kPa can be used to noninvasively
rule in the presence of clinically significant PH (CSPH) in
ACLDpatients [8]. However, LSMdoes not solely reflect liver
fibrosis but can reflect many other conditions [13, 20–22],
including liver congestion [22]. This is why LSM could play
a role in the evaluation of BCS, since the hepatic venous flow
obstruction found in these patients typically leads to liver
congestion and a post-sinusoidal form of PH [6, 23]. This
hypothesis is in fact supported by initial data from murine
models [24] and two studies that performed LSM in BCS
patients [11, 12].
SSM is another more recent noninvasive method that can
assess the degree of portal hypertension. In fact, SSM reflects
the congestion and other structural changes [25, 26] occur-
ring in the spleen as direct consequences of the increased
portal pressure, irrespectively of its cause [6]. Therefore, it is
considered a direct and more suitable surrogate of PH than
LSM, with consistent evidence showing a better performance
of SSM in the prediction of clinically significant PH (CSPH)
[27, 28] or EV [29] in patients with advanced chronic liver
disease (ACLD). However, to date no data are available on
SSM values in BCS patients.
Based on our series of BCS patients, we believe that
the implementation of LSM and SSM in the assessment
of BCS patients has several benefits. Firstly, patients with
acute nonfulminant manifestation of BCS present with severe
liver congestion and consequent markedly increased portal
pressure, as reflected by near-the-upper-limit values of LSM
and SSM (75 kPa). Such values are very uncommon in other
liver diseases, such as ACLD or other conditions that lead to
hepatic congestion [30, 31]. For instance, out of 643 ACLD
patients included in one of our previous studies [7], only three
patients presented both LSM and SSM at 75 kPa. Therefore,
extremely high values of both LSM and SSM could be very
suggestive of BCS in a decompensated patient with unclear
liver etiology or with an inconclusive first ultrasound exam.
This information could lead clinicians to request further
imaging studies to confirm BCS diagnosis.
Moreover, TE values found at diagnosis can stratify the
severity of BCS disease. For instance, all patients (1-3) with
high LSM and SSM values at diagnosis developed recurrent
decompensating events and underwent TIPS placement or
OLT within a few years. Maximum TE values were main-
tained or found also before TIPS placement, thus confirming
the findings of Mukund et al., who reported median values
of 75 kPa before such intervention [11]. In contrast, the
markedly lower TE values at diagnosis found in patients 6
and 7 were associated with milder chronic forms of BCS
presentation; in fact, these patients did not develop events
of clinical decompensation during follow-up and did not
require invasive interventions, such as TIPS.
Our series thus presents new and very promising results
regarding TE as a prognostic tool in BCS patients. This is the
first study report that shows LSM and SSM values at BCS
diagnosis in patients with different disease severity. The only
two previous studies [11, 12] evaluating LSM in these patients
were limited to its evaluation in patients with severe BCS and
only before (and after) TIPS placement. Furthermore, values
at TE evaluation seem to correspond to the degree of liver
congestion and PH, as they clearly differ between patients
with and without decompensated disease (patients 1-4 vs 6-
7). Of note, the SSM values in patients 6 and 7 were below
our previously described cut-off (54 kPa) for the prediction
of hepatic decompensation in ACLD patients [10].We believe
that the measurement at baseline of both these parameters
could better stratify the risk of PH-related complications and
help clinicians to identify patients with more severe PH,
who are more prone to recurrent decompensating events
and require earlier TIPS placement or OLT. TE evaluation
could therefore at least improve the prognostic information
provided by the currently available PIs.
Whether LSM or SSM is the more informative parameter,
it is still to be determined. We found a discrepancy between
LSM and SSM values only in the two compensated patients
(patients 6 and 7), due to higher LSM values in patient 6
(34.8 vs 14.3 kPa) and higher SSM values in patient 7 (38
kPa vs 47.2 kPa). However, clinical data, such as the pres-
ence of splenomegaly and periumbilical vein recanalization,
suggested a higher portal pressure in patient 7, which could
justify higher SSM (47.2 kPa). In patient 6, on the other hand,
LSM could be related to a modest and heterogenous liver
congestion, which is common in BCS patients and could
justify our results. In fact, in this patient only the right HV
was occluded, whose drainage area corresponded to the side
where the LSMwas performed.This suggests that SSM could
be a more accurate predictor of disease severity, as it reflects
PH directly and may not be influenced by the heterogeneity
of BCS.
Response to therapy is another fundamental point to
consider after BCS diagnosis. Doppler-US is the preferred
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noninvasive tool to monitor the dynamic changes in the level
of obstruction over time/after therapy [1]; however, it lacks
sensitivity in evaluating short- and long-term outcomes after
therapy [32]. To date, two papers [11, 12] have evaluated short-
term changes in LSM after derivative therapy in BCS patients.
Mukund et al. [11] showed for the first time that LSM, assessed
byTE, significantly decreased 24 hours after the endovascular
intervention, but no correlation between changes in LSM and
the pressure gradient was found. Later on, Wang et al. [12]
confirmed that LSM, evaluated by share-wave elastography,
significantly decreased two days after balloon angioplasty.
The authors also demonstrated that before-treatment LSM
values significantly correlated with hepatic venous gradient,
but notwith liver fibrosis degree, proposing LSMas a sensitive
NIT to monitor hemodynamic changes after therapy in BCS
patients. However, the follow-up period in these two studies
was short (up to six months) and the relationship between
LSM changes and clinical outcomes after treatment was not
investigated.
In the present series, in most of the patients LSM became
lower after therapy. Considering the retrospective design of
the study, TE was not systematically repeated at scheduled
time-points (i.e. 1 day, 3 months) after TIPS, thus our results
are not comparable to the above-mentioned studies. How-
ever, we described for the first time LSM and SSM values for
up to ten years after TIPS implementation. Most importantly,
LSM not only decreased after TIPS placement in patients 1
and 4, but its values were also below the threshold of 10 kPa
for ACLD. In our view, this is an important result, as it could
show how liver parenchyma, and therefore liver function,
is preserved in some BCS patients. These are the patients
that mostly benefit from derivative interventions such as
TIPS, and being able to identify them through repeated TE
evaluations could be very helpful for clinicians.
On the other hand, a lack of decreasing LSM might help
identify subjects who remain at risk of decompensation. This
could reflect obstruction or the suboptimal efficacy of TIPS
(as in patient 7), but most importantly, it could also reveal the
“real” BCS-related cirrhotic patients (i.e., persistently high
LSM values despite patent TIPS). Liver cirrhosis is often
improperly used or erroneously diagnosed in BCS patients
(i.e., patients 3 and 5), mostly due to the presence of US
signs that are not unique to with this condition, such as
caudate lobe hypertrophy and nodularity. Identifying BCS-
related cirrhotic patients would be beneficial in selecting the
best candidates for OLT, as a risk of decompensation in these
patients is correlated with liver function impairment, rather
than congestion.
As far as SSM is concerned, a slight decrease due to spleen
decongestion may be observed after TIPS placement (i.e.,
patient 1) or anticoagulation (i.e., patient 6 and 7). How-
ever, these changes are less evident than the rapid decrease
described for LSM as a result of liver decongestion. Persistent
SSMvalues could reflect the long-standing structural changes
that occur in the spleen due to PH development [25],
together with the fact that there is still a risk of PH-driven
complications in these patients [1]. However, the role of SSM
changes after TIPS placement still needs to be clarified, also
in the context of ACLD.
In conclusion, we believe that TE will soon become a
valid prognostic tool in the context of vascular liver diseases,
just as it is today for ACLD patients of viral etiology. At
BCS diagnosis, LSM and especially SSM could stratify for
PH severity and better identify patients that require TIPS
placement. However, little information on the underlying
chronic liver disease can be obtained, as LSM in these
patients reflects the congestion rather than the fibrosis of the
liver. Moreover, persistently high TE values despite derivative
therapy could reveal the patients with real ACLD and liver
function impairment; in these patients, OLT should be
considered. Future multicentre studies in larger cohorts are
highly encouraged in order to fully explore the potential of
NITs in BCS.
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